# Trump’s 100% drug tariffs threaten India’s pharma exports 2026-08-24T12:19:21+00:00 | World & Diplomacy | Indian Opinion Desk Corroboration: 1 independent outlet US President Donald Trump has announced plans to impose 100% tariffs on imported generic medicines from August 2028, rising to 200% after one year, in a move analysts say could disrupt India's low-cost, export-driven pharmaceutical model and its status as the 'pharmacy of the world'. Generic drugs account for 90% of prescriptions in the US, and the US market contributes about 35% of Indian pharma revenues. Leading Indian firms generated nearly $11 billion in US sales in the financial year ending March 2026. Trump said the two-year transition period is meant to allow firms to relocate manufacturing to the US. Vivek Mishra of the Observer Research Foundation said Indian companies may need to set up bases in the US and face supply chain disruptions. ## Indian Opinion Analysis India's generic drug industry relies on thin margins and high volumes, so a 100% tariff would erase price advantage over US-made drugs. The 2028 start date gives time for lobbying or legal challenges, but the US goal is to reshore strategic drug production. Indian firms like Sun Pharma and Dr Reddy's already have US plants, but smaller exporters face existential risk. The next signal to watch is whether any trade exemptions emerge in Trump's 2025 tariff review cycle. ## Coverage - scmp.com Leads with analyst warning but presents tariff details factually without partisan slant. This story was synthesised by AI from the source linked above. Tags: Donald Trump, generic drugs, Indian pharma industry, Observer Research Foundation, US tariffs Canonical: https://indianopinion.org/trumps-100-drug-tariffs-threaten-indias-pharma-exports/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/trumps-100-drug-tariffs-threaten-indias-pharma-exports/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes. How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/